Use of Bosentan in Pediatric Pulmonary Hypertension

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2011;17(11) 

In This Article

Abstract and Introduction


The treatment options for children with pulmonary arterial hypertension (PAH) have expanded considerably over the previous decade, and include nitric oxide, prostacyclin analogues, phosphodiesterase inhibitors, and endothelin antagonists. Bosentan, the first endothelin antagonist on the market in the United States, was approved by the Food and Drug Administration (FDA) on November 20, 2001.[1,2] Although not currently approved for use in children, numerous case series and small-scale studies conducted over the past decade suggest a role for bosentan in this population.[3–7] This issue of Pediatric Pharmacotherapy will review these papers and provide recommendations for bosentan use in children.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: